Literature DB >> 21853427

Utility of panendoscopy for the detection of unknown primary head and neck cancer in patients with a negative PET/CT scan.

Kavita M Pattani1, Michael Goodier, David Lilien, Todd Kupferman, Gloria Caldito, Cherie-Ann O Nathan.   

Abstract

We conducted a retrospective review of the records of 23 patients who had been diagnosed with regionally metastatic head and neck squamous cell carcinoma from an unknown primary tumor. Our goal was to assess the utility of panendoscopy in locating the primary tumor in those patients whose positron-emission tomography/computed tomography (PET/CT) findings were negative. Overall, we found that PET/CT had correctly identified the unknown primary in 12 of the 23 patients (52%); panendoscopy confirmed this finding in all 12. Of the remaining 11 patients, however, panendoscopy located the primary tumor in only 1 (9%). In this era of cost containment and ongoing advances in imaging and transnasal esophagoscopy, it is important to revisit the workup of an unknown primary in patients with a negative PET/CT scan. There are various advantages and disadvantages to performing panendoscopy with biopsy in patients with an unknown primary and a negative PET/CT scan, but our results and the findings of others indicate that it will detect the primary in only about 10% of these cases. We recommend careful selection of patients who are to undergo panendoscopy for the routine workup of an unknown primary.

Entities:  

Mesh:

Year:  2011        PMID: 21853427     DOI: 10.1177/014556131109000818

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  8 in total

1.  Clinicopathological characteristics of carcinoma from unknown primary in cervical lymph nodes.

Authors:  Daniel Weiss; Mario Koopmann; Markus Stenner; Eleftherios Savvas; Claudia Rudack
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-03-17       Impact factor: 2.503

2.  Role of panendoscopy in identifying and managing risk of head and neck squamous cell carcinoma in routine follow-up: a retrospective clinical evaluation.

Authors:  Adrian Münscher; Susanne Sehner; Jegane Taleh; Silke Tribius; Nicolaus Möckelmann; Arne Böttcher; Amit Gulati; Carsten Dalchow; Till Clauditz; Rainald Knecht
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-07       Impact factor: 2.503

3.  Transoral robotic approach to carcinoma of unknown primary.

Authors:  Kasim Durmus; Sanjeet V Rangarajan; Matthew O Old; Amit Agrawal; Theodoros N Teknos; Enver Ozer
Journal:  Head Neck       Date:  2013-09-02       Impact factor: 3.147

4.  Diagnostic Value of Lingual Tonsillectomy in Unknown Primary Head and Neck Carcinoma Identification After a Negative Clinical Workup and Positron Emission Tomography-Computed Tomography.

Authors:  Chad K Sudoko; Marc A Polacco; Benoit J Gosselin; Joseph A Paydarfar
Journal:  Front Oncol       Date:  2018-04-20       Impact factor: 6.244

5.  A systematic review on Transoral robotic surgery (TORS) for carcinoma of unknown primary origin: Has tongue base mucosectomy become indispensable?

Authors:  Stijn van Weert; Johannes A Rijken; Francesca Plantone; Elisabeth Bloemena; Marije R Vergeer; Birgit I Lissenberg-Witte; C René Leemans
Journal:  Clin Otolaryngol       Date:  2020-05-25       Impact factor: 2.597

Review 6.  Updates in the management of unknown primary of the head and neck.

Authors:  Sandhya Kalavacherla; Parag Sanghvi; Grace Y Lin; Theresa Guo
Journal:  Front Oncol       Date:  2022-09-15       Impact factor: 5.738

Review 7.  The role of transoral robotic surgery, transoral laser microsurgery, and lingual tonsillectomy in the identification of head and neck squamous cell carcinoma of unknown primary origin: a systematic review.

Authors:  Terence S Fu; Andrew Foreman; David P Goldstein; John R de Almeida
Journal:  J Otolaryngol Head Neck Surg       Date:  2016-05-04

Review 8.  Transoral robotic surgery for oropharyngeal cancer: patient selection and special considerations.

Authors:  R Michael Baskin; Brian J Boyce; Robert Amdur; William M Mendenhall; Kathryn Hitchcock; Natalie Silver; Peter T Dziegielewski
Journal:  Cancer Manag Res       Date:  2018-04-20       Impact factor: 3.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.